Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers.

Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ.

Int J Clin Exp Pathol. 2009;2(5):444-55. Epub 2009 Feb 9.

2.

Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.

Bhargava R, Beriwal S, Striebel JM, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):113-8. doi: 10.1097/PAI.0b013e3181b94ff1.

PMID:
19801938
3.

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.

Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.

Cancer. 2010 Mar 15;116(6):1431-9. doi: 10.1002/cncr.24876. Erratum in: Cancer. 2011 May 15;117(10):2238.

4.

Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.

Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA.

BMC Cancer. 2010 May 21;10:223. doi: 10.1186/1471-2407-10-223.

5.

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE.

BMC Womens Health. 2014 Aug 29;14:102. doi: 10.1186/1472-6874-14-102.

6.

Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.

Ribelles N, Perez-Villa L, Jerez JM, Pajares B, Vicioso L, Jimenez B, de Luque V, Franco L, Gallego E, Marquez A, Alvarez M, Sanchez-Muñoz A, Perez-Rivas L, Alba E.

Breast Cancer Res. 2013;15(5):R98.

7.

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases.

Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P.

Breast Cancer (Auckl). 2013;7:23-34. doi: 10.4137/BCBCR.S10701. Epub 2013 Feb 13.

8.

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

Bhargava R, Dabbs DJ, Beriwal S, Yildiz IA, Badve P, Soran A, Johnson RR, Brufsky AM, Lembersky BC, McGuire KP, Ahrendt GM.

Mod Pathol. 2011 Mar;24(3):367-74. doi: 10.1038/modpathol.2010.209. Epub 2010 Nov 19.

9.

Molecular subtyping of male breast cancer by immunohistochemistry.

Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ.

Mod Pathol. 2012 Mar;25(3):398-404. doi: 10.1038/modpathol.2011.174. Epub 2011 Nov 4.

10.

Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW.

Breast. 2012 Feb;21(1):50-7. doi: 10.1016/j.breast.2011.07.008. Epub 2011 Aug 23.

PMID:
21865043
11.

Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.

Bhargava R, Beriwal S, McManus K, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2011 May;19(3):218-25. doi: 10.1097/PAI.0b013e3181ffc58c.

PMID:
21217522
12.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
13.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.

PMID:
21472434
14.

Prognostic significance of molecular classification of breast invasive ductal carcinoma.

Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J.

Arch Gynecol Obstet. 2009 Jul;280(1):43-8. doi: 10.1007/s00404-008-0867-1. Epub 2008 Dec 11.

PMID:
19082617
15.

Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.

Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I, Inic I, Pupic G, Jancic S.

Clin Med Insights Oncol. 2014 Sep 11;8:107-11. doi: 10.4137/CMO.S18006. eCollection 2014.

16.

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C.

J Clin Oncol. 2009 Mar 10;27(8):1168-76. doi: 10.1200/JCO.2008.18.1024. Epub 2009 Feb 9.

17.

Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer.

Kayahan M, İdiz UO, Gucin Z, Erözgen F, Memmi N, Müslümanoğlu M.

J Breast Health. 2014 Oct 1;10(4):201-208. doi: 10.5152/tjbh.2014.1777. eCollection 2014 Oct.

18.

Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients.

Tamaki K, Ishida T, Tamaki N, Kamada Y, Uehara K, Miyashita M, Amari M, Tadano-Sato A, Takahashi Y, Watanabe M, McNamara K, Ohuchi N, Sasano H.

Breast Cancer. 2014 May;21(3):325-33. doi: 10.1007/s12282-012-0387-5. Epub 2012 Jul 11.

PMID:
22782361
19.
20.

Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.

Xue C, Wang X, Peng R, Shi Y, Qin T, Liu D, Teng X, Wang S, Zhang L, Yuan Z.

Cancer Sci. 2012 Sep;103(9):1679-87. doi: 10.1111/j.1349-7006.2012.02339.x. Epub 2012 Jul 4.

Supplemental Content

Support Center